European Pharmaceutical Review

AUGUST 24, 2022

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. cancer agent or disease-relevant toxin. 2 The role of the antibody is to deliver the payload to a specific site such as a cancer cell.

Engineering 92

Engineering Side effects Marketing Patients 92

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Physicians 52

Physicians Marketing Patients Manufacturing 52

pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. It is estimated there are around 1,500 people in the US who could be eligible for treatment with the therapy.

FDA 52

FDA Insurance Patients Medical 52

pharmaphorum

DECEMBER 12, 2022

“This is exciting news because existing treatments fail to improve platelet counts for as many as 30% of adults with chronic ITP,” commented said Catherine Broome of Georgetown Lombardi Cancer Centre in Washington DC, the trial’s lead investigator. All told, 51.2%

Side effects 52

Side effects Sales Competition Patients 52

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

Medicine 52

Medicine FDA Recruitment Patients 52

Pharmaceutical Technology

MAY 15, 2023

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Medicine 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. This approach remains logistically complex, which builds the desire for allogeneic treatments that can be manufactured from unrelated donors on a larger scale. We also have the challenge of delivery.

Food and Drug Administration 59

Food and Drug Administration Engineering Patients Education 59

PM360

NOVEMBER 12, 2023

By tapping into these insights, healthcare organizations can craft campaigns, treatments, and messaging that resonate deeply with their populations’ real-life challenges and aspirations, fostering genuine connections.” Myla Maloney, Chief Growth Officer, Premier, Inc.

Marketing 59

Marketing Media Patients Healthcare 59

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Electronics 88

Electronics Patients Management Insurance 88

pharmaphorum

NOVEMBER 28, 2022

“By open sourcing Substra and releasing two landmark federated innovations to researchers, we hope to unleash a wave of collaborative research that will spur on the development of the next generation of treatments. The post Owkin taps Linux Foundation to open-source its AI learning software appeared first on.

Training 70

Training Medical Pharma Healthcare 70

PM360

APRIL 7, 2023

This option grows more critical as new therapies become available with price tags as high as $3.5 Any breakdown in this communication channel seriously undermines patient access to treatment. Sanofi Promises Money Back for Discontinued Blood Disorder Treatment – In Some Cases.” million for the new hemophilia gene therapy.

Manufacturing 52

Manufacturing Marketing Patients Safety 52

Evolve Your Success

JUNE 13, 2023

Kelly currently thrives in diagnostic testing sales, specifically in a department that deals with skin cancer prognosis. We’re looking at skin cancer like melanoma and squamous cell carcinoma. We provide a service for cancer patients. That’s a good thing that you don’t have any cancer patients that you’ve seen.

Sales 52

Sales Medical sales Medical Doctors 52

PM360

SEPTEMBER 7, 2023

Mason learned that lesson while working with argenx to launch VYVGART (efgartigimod alfa-fcab), the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disease. We also put big pull tags on the little pouches that held the items.

Patients 105

Patients Pharma Education Doctors 105

European Pharmaceutical Review

NOVEMBER 10, 2022

The complexity of these medicines compared to small molecule drugs brings many challenges when developing safe and effective treatments, particularly at the early stages of drug discovery. BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). About the authors.

Medicine 103

Medicine Distribution Engineering Electronics 103

European Pharmaceutical Review

DECEMBER 27, 2023

Product distribution requires shipping of apheresis starter materials, either cryopreserved or fresh (depending on the product), to the manufacturing site as well as shipping of final cryopreserved products to treatment centres. This is in addition to its considerable price tag. 6-8 Clinical recommendations also change.

Manufacturing 92

Manufacturing Food and Drug Administration Patients Pharma 92

Pharmaceutical Technology

MARCH 17, 2023

Finance-based risk sharing agreements tend to have a specified budget cap discount whilst performance-based agreements rely on a specified endpoint to determine response to treatment and whether a refund or reimbursement should happen. In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”.

Marketing 102

Marketing Pharma Pharmaceutical Healthcare 102

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication.

Healthcare 40

Healthcare Healthcare Marketing Pharma 40